FDA Issues Warning Letter to Tianjin Zhongan Pharmaceutical - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

FDA Issues Warning Letter to Tianjin Zhongan Pharmaceutical

PTSM: Pharmaceutical Technology Sourcing and Management
Volume 10, Issue 7

FDA issued a warning letter to Tianjin Zhongan Pharmaceutical on June 10, 2014 for cGMP violations for APIs that FDA identified in an inspection of the Tianjin, China plant from Sept. 23 to Sept. 27, 2013. Deviations cited included failure to adequately complete and follow written procedures for cleaning equipment and to maintain adequate records of major equipment usage, failure to conduct adequate change control, and failure to adequately review and investigate product deviations.

An inspection found that employees did not adequately clean equipment after use. FDA also noted that the firm "did not maintain equipment logs or other documents that adequately record manufacturing operations performed on individual pieces of equipment." 

Although employees had been trained in change control procedures, FDA found that they failed to comply with procedures and that the company's response did not give enough detail on how compliance would be ensured.

Inspectors found that the company failed to adequately investigate deviations and did not adequately control certificates of analysis. FDA also cited concerns about inadequate qualification of critical production equipment.

FDA concluded, "Your inability to detect and prevent the above deficient practices, as well as other deficiencies found during the inspection, indicate that your current quality system is ineffective at achieving overall compliance with cGMP." The agency recommended that the firm engage a third-party consultant with appropriate cGMP expertise.

Source: FDA

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
29%
Breakthrough designations
10%
Protecting the supply chain
43%
Expedited reviews of drug submissions
10%
More stakeholder involvement
10%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests
Source: PTSM: Pharmaceutical Technology Sourcing and Management,
Click here